Tag:
Sarepta Therapeutics
Latest Headlines
Latest Headlines
Sarepta slips as FDA seeks more data on eteplirsen
Sarepta Therapeutics has kept hopes alive for gaining accelerated approval for its lead drug eteplirsen for Duchenne muscular dystrophy.
Sarepta sustains high hopes for DMD drug eteplirsen with more PhII data
Sarepta Therapeutics spotlighted continued benefits of treatment with its lead drug eteplirsen today in one of the most closely watched Phase IIb studies in the biotech industry.
Biotech gamblers crowd high-stakes game for Sarepta
For most biotechs, the sit-down with the FDA after a positive Phase II study is a fairly routine affair designed to point them down the path to a pivotal program. For Sarepta Therapeutics, though, it represents a strategic crossroad rarely seen in this industry. In one direction lies a lengthy Phase III trial, while the other path points straight to a major new market for Duchenne muscular dystrophy, a terrible affliction faced by a small group of boys.
UPDATED: Biotech PTC reloads coffers with $60M for late-stage DMD drug
PTC Therapeutics has scored new financing to bankroll development of a compound for certain types of Duchenne muscular dystrophy and cystic fibrosis.
Sarepta capitalizes on hot streak with $125M financing
Sarepta Therapeutics has seen demand for its stock spike since the company revealed impressive long-term data two months ago from a mid-stage study of its therapy eteplirsen in patients with Duchenne muscular dystrophy.
UPDATED: Sarepta shares rocket up on stellar muscular dystrophy trial results
Among a small group given the highest dose of eteplirsen, patients were able to outpace the placebo arm by 89.4 meters in a six-minute walk test.
Talent hunt spurs Sarepta's cross-country move to booming Boston hub
Score another win for Boston in the high-stakes game of developing a thriving biotech hub. Xconomy' s Luke Timmerman has the scoop this morning that the promising Seattle-based biotech Sarepta is making the big move to Cambridge, MA.
Report precedes stock jump for biotech Sarepta
Bothell, WA-based Sarepta's shares were up 14.29% to $14.40 per share at the close of trading on Thursday.
Sarepta rockets up as extension study delivers promising results for DMD
It took a few extra months of treatment, but a group of patients in a key Phase IIb study of Sarepta Therapeutics' (formerly AVI) Duchenne muscular dystrophy therapy eteplirsen registered much better walking distance compared to a placebo arm.
